Drug Companies Give Million-Dollar Boost to Lobbying (Corrected)
Five pharmaceutical companies have reported million-dollar increases in their spending on lobbying the federal government during the first quarter of 2014.
Pfizer Inc., Novartis, Johnson & Johnson Services, Bayer Corporation, and Merck & Company have each boosted their lobbying of the executive and legislative branches.
Here are the top pharmaceutical spenders in the first quarter of 2014:
Pharmaceutical Research & Manufacturers (PhRMA) $4,680,000 – up from $4,050,000 in 2013 Q4.
Pfizer Inc. $3,190,000 – up from $2,090,000.
Novartis $2,580,000 – up from $920,000.
Amgen USA Inc. $2,560,000 – up from $2,330,000.
Eli Lilly & Co. $2,086,000 – down from $2,430,000.
Johnson & Johnson Services $2,110,000 – up from $860,000.
Bayer – $2,040,000, up from $1,000,000.
Merck & Co. $2,000,000 – up from $820,000
Glaxosmithkline $1,630,000 – up from $421,000. (Corrected)
Sanofi US Services Inc. $1,570,000 – up from $790,000.
AbbVie $1,450,000 – up from $600,000.
Genentech Inc. $1,152,000 – down from 1,220,700.
Teva Pharmaceuticals USA Inc. $1,160,000 – up from $800,000.
AstraZeneca* $1,030,000 – up from $560,000.
Novo Nordisk Inc. $710,000 – down from 820,000.
Bristol-Myers Squibb Co. $520,000 – down from 740,000.
Abbott Laboratories $410,000 – down from $700,000.
*5/4 Update. AstraZeneca amended their 2013 Q4 report to show $560,000.
